Navigation Links
Uroplasty Provides Update On PTNS Reimbursement

MINNEAPOLIS, Dec. 4, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today provided an update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation (PTNS) procedures delivered via the Company's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.

"The number of patients with insurance coverage for PTNS procedures delivered via our Urgent PC system continues to grow and presents us with the opportunity for sustainable strong growth," said Rob Kill, President & CEO.  "Based on the latest reimbursement developments, including the decision of National Government Services (NGS) to continue its existing non-coverage policy for PTNS, we anticipate Urgent PC will exit calendar 2013 with approximately 40 million Medicare lives under coverage, an increase from 37 million a year ago, and approximately 106 million private insurer lives under coverage, up from 87 million a year ago."

The Centers for Medicare and Medicaid Services (CMS) released the final 2014 Physician Fee Schedule, and the Relative Value Units (RVUs) for PTNS reimbursement are substantially the same as the proposed reimbursement published in July. The final reimbursement amount for 2014 is subject to any potential Congressional action as it relates to the Medicare Sustainable Growth Rate (SGR) formula.  Further, PTNS was one of several hundred codes that were noted as a potentially misvalued code earlier this year.  While many of these codes had reimbursement reductions, CMS has indicated further review of PTNS is warranted, and as a result, CMS will be gathering additional feedback before a final decision is made.  The final decision could result in an increase, a decrease or no change in the reimbursement rate for PTNS. Any change to the reimbursement rate due to this review is not expected to be published until November 2014 and will become effective beginning in January 2015.

In addition, the Company reported today that Health Care Service Corporation (HCSC), the largest customer-owned health insurance company in the United States, recently announced extended PTNS coverage for treatment of OAB. Effective December 15, 2013, HCSC Blue Cross Blue Shield of Illinois, Montana, New Mexico, Oklahoma and Texas will extend coverage of PTNS treatment for up to three years for patients showing continued improvement after the first year of treatment. 

"Our sales organization is successfully executing our initiatives, and we continue to expect our fiscal third quarter year over year revenue growth rate for U.S. Urgent PC will be in the high teens," added Mr. Kill.  "With Uroplasty and other therapies currently penetrating less than one percent of the OAB market for patients who fail drug therapies, we believe there is more than ample opportunity to  grow our business."

Uroplasty is participating in the 25th Annual Piper Jaffray Healthcare Conference today, and management expects to provide an update on these developments as well as other corporate initiatives during a webcast broadcast of a fireside chat beginning at 3:30 pm ET.  Those interested in joining the webcast may access it through Uroplasty's website at An archived replay of the presentation will be available for 90 days following the event.

About Overactive Bladder
Overactive bladder (OAB) is a chronic condition that affects approximately 34 million US adults.  The symptoms include urinary urgency, frequency and urge incontinence.  The Urgent PC Neuromodulation System is the only FDA cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy.

About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at

For Further Information:
Uroplasty, Inc.
Brett Reynolds, SVP and CFO

EVC Group
Leigh Salvo (Investors)/Janine McCargo (Business Media)

SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty To Participate In The Piper Jaffray Healthcare Conference
2. Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Humana, Inc.
3. Uroplasty Sets New Quarterly Revenue Record During Fiscal Second Quarter 2014
4. Uroplasty To Participate In The Craig-Hallum Alpha Select Conference
5. Class Action Lawsuit Against Uroplasty Dismissed
6. Uroplasty Appoints Brett Reynolds As Chief Financial Officer
7. Uroplasty Reports Fiscal First Quarter 2014 Financial Results
8. Uroplasty Completes Internal Control Review; Files Form 10-K for Fiscal 2013
9. Uroplasty Announces Delay in Filing Form 10-K
10. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2013 Financial Results
11. Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Wisconsin Physicians Services
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Marker Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology:
(Date:11/28/2015)... , ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until ... most savings. , With possible savings of up to 20% off orders $80 or more ... of the website every few hours. , As a competitive e-commerce website for skin care ...
(Date:11/27/2015)... ... ... According to an article published November 6th by The Telegraph, ... British Columbia suggested that laws requiring bicyclists to wear helmets may not actually decrease ... reason for the controversial conclusion is that, while helmets have certainly prevented a great ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... A simply ... Jones, is an interesting show that delves into an array of issues that are ... that could benefit from open dialogue, this show is changing the subjects consumers focus ...
Breaking Medicine News(10 mins):